Related Experiment Video
Updated: Sep 5, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and
J R Azanza1, J Mensa, J González Del Castillo
1José Ramón Azanza, Servicio de Farmacología Clínica. Clínica Universitaria de Navarra. Pamplona. Spain. jrazanza@unav.es.
Abstract:
Paxlovid (nirmatrelvir plus ritonavir) is a new oral antiviral therapeutic for the treatment and post-exposure prophylaxis of COVID-19. Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease, while ritonavir is used as a CYP3A inhibitor in low doses to slow the metabolism of nirmatrelvir, thus enhancing their therapeutic effect. The isoenzyme CYP3A4 is responsible for at least part of the oxidative metabolism of approximately 60% of available medications and ritonavir is therefore a significant source of drug interactions. We describe here the drugs that are contraindicated or should be used with or without precautions when Paxlovid (nirmaltrevir plus ritonavir) should be administered according to each fact sheet in force at the Spanish Agency for Medicines and Health Products.
Related Concept Videos
Drug Classes and Categories
Effects of Chemicals: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Factors Affecting Drug Response: Overview

